Most Recent Articles by Randi Hernandez
Close postmarketing monitoring will be especially crucial for drugs approved with a breakthrough therapy designation, as many of them were given a pass on the basis of a single pivotal trial.
Drug developers relying on CRISPR-Cas9 platforms for the creation of gene therapies saw their shares slide when it was revealed that the technique may inadvertently cause disruptions of larger chunks of DNA than previously thought.
Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.
Although they fall outside official testing guidelines for lung cancer, people who have smoked at all in their lifetime could still be at risk for the disease. Researchers propose a biomarker test for 4 proteins could identify more individuals that could benefit from subsequent screening.
According to recent research, scientists may not need to rely on the use of viral vectors to edit the genes of primary immune cells when creating cell and gene therapies.
More Articles by Randi Hernandez
Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell LymphomaJul 05,2018
Q&A With Frank Luh, MD, MS, MHA and Yun Yen, MD, PhD, FACP: Looking to Broaden CMS Coverage for NGS TestsJul 04,2018
Medicare Reimbursement Restrictions on Next-Generation Sequencing Could Hinder Clinical Decision-MakingJun 28,2018
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials